Intuitive Surgical, Inc. (NASDAQ:ISRG) Director Amal M. Johnson Sells 4,635 Shares

Intuitive Surgical, Inc. (NASDAQ:ISRG) Director Amal M. Johnson sold 4,635 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $566.60, for a total value of $2,626,191.00. Following the completion of the transaction, the director now directly owns 12,275 shares of the company’s stock, valued at $6,955,015. The trade was a 27.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Intuitive Surgical Price Performance

ISRG stock opened at $572.71 on Thursday. Intuitive Surgical, Inc. has a 1 year low of $364.17 and a 1 year high of $616.00. The firm has a market capitalization of $203.99 billion, a PE ratio of 92.08, a price-to-earnings-growth ratio of 5.19 and a beta of 1.39. The business has a 50 day simple moving average of $548.70 and a 200-day simple moving average of $507.04.

Institutional Trading of Intuitive Surgical

Large investors have recently added to or reduced their stakes in the stock. State Street Corp boosted its position in shares of Intuitive Surgical by 1.4% during the 3rd quarter. State Street Corp now owns 15,050,121 shares of the medical equipment provider’s stock valued at $7,393,673,000 after acquiring an additional 210,363 shares during the last quarter. FMR LLC raised its stake in Intuitive Surgical by 8.3% during the third quarter. FMR LLC now owns 10,971,085 shares of the medical equipment provider’s stock worth $5,389,765,000 after purchasing an additional 838,793 shares during the period. Geode Capital Management LLC boosted its holdings in Intuitive Surgical by 1.9% in the 3rd quarter. Geode Capital Management LLC now owns 7,512,925 shares of the medical equipment provider’s stock valued at $3,677,194,000 after purchasing an additional 143,440 shares during the last quarter. Fisher Asset Management LLC increased its holdings in shares of Intuitive Surgical by 1.8% during the 3rd quarter. Fisher Asset Management LLC now owns 4,782,381 shares of the medical equipment provider’s stock worth $2,349,441,000 after buying an additional 86,208 shares during the last quarter. Finally, Baillie Gifford & Co. lifted its holdings in Intuitive Surgical by 0.6% in the third quarter. Baillie Gifford & Co. now owns 3,848,547 shares of the medical equipment provider’s stock valued at $1,890,676,000 after acquiring an additional 24,183 shares during the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ISRG has been the subject of several analyst reports. JPMorgan Chase & Co. boosted their target price on shares of Intuitive Surgical from $575.00 to $675.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Morgan Stanley upgraded shares of Intuitive Surgical from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $522.00 to $650.00 in a research report on Monday, December 2nd. Citigroup lifted their price target on Intuitive Surgical from $640.00 to $711.00 and gave the company a “buy” rating in a research note on Friday, January 24th. CICC Research began coverage on Intuitive Surgical in a research report on Monday. They set a “neutral” rating and a $550.00 price target on the stock. Finally, Royal Bank of Canada boosted their price objective on Intuitive Surgical from $611.00 to $641.00 in a research report on Monday. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $613.10.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.